Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,414
archived clinical trials in
Overactive Bladder

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Clinical Research of Philadelphia LLC
mi
from
Philadelphia, PA
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Clinical Research of Philadelphia LLC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Advanced Clinical Concepts
mi
from
West Reading, PA
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Advanced Clinical Concepts
mi
from
West Reading, PA
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Greater Providence Clinical Research, Llc
mi
from
Warwick, RI
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Greater Providence Clinical Research, Llc
mi
from
Warwick, RI
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Radiant Research, Inc.
mi
from
Anderson, SC
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Radiant Research, Inc.
mi
from
Anderson, SC
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Fellows Research Alliance, Inc.
mi
from
Bluffton, SC
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Fellows Research Alliance, Inc.
mi
from
Bluffton, SC
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Medical Research South
mi
from
Charleston, SC
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Medical Research South
mi
from
Charleston, SC
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Hillcrest Clinical Research, LLC
mi
from
Simpsonville, SC
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Hillcrest Clinical Research, LLC
mi
from
Simpsonville, SC
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Meridian Clinical Research
mi
from
Dakota Dunes, SD
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Meridian Clinical Research
mi
from
Dakota Dunes, SD
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Jackson Clinic, PA
mi
from
Jackson, TN
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Jackson Clinic, PA
mi
from
Jackson, TN
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Advanced Therapeutics, Inc.
mi
from
Johnson City, TN
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Advanced Therapeutics, Inc.
mi
from
Johnson City, TN
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Tennesse Women's Care
mi
from
Nashville, TN
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Tennesse Women's Care
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Tekton Research
mi
from
Austin, TX
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
DiscoverResearch, Inc.
mi
from
Bryan, TX
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
DiscoverResearch, Inc.
mi
from
Bryan, TX
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Research Across America
mi
from
Carrollton, TX
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Research Across America
mi
from
Carrollton, TX
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Research Across America
mi
from
Dallas, TX
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Research Across America
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
DCOL Center for Clinical Research
mi
from
Longview, TX
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
DCOL Center for Clinical Research
mi
from
Longview, TX
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Quality Research
mi
from
San Antonio, TX
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Quality Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Radiant Reseach, Inc.
mi
from
San Antonio, TX
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Radiant Reseach, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Wasatch Clinical Research
mi
from
Salt Lake City, UT
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Wasatch Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
The Group for Women
mi
from
Norfolk, VA
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
The Group for Women
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Integrity Medical Research
mi
from
Mountlake Terrace, WA
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Integrity Medical Research
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Valley Women's Clinic
mi
from
Renton, WA
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Valley Women's Clinic
mi
from
Renton, WA
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated:  11/27/2013
Seattle Women's Health, Research and Gynecology
mi
from
Seattle, WA
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Status: Enrolling
Updated: 11/27/2013
Seattle Women's Health, Research and Gynecology
mi
from
Seattle, WA
Click here to add this to my saved trials
Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder
A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Solifenacin and Percutaneous Tibial Nerve Stimulation in Patients With Refractory Overactive Bladder
Status: Enrolling
Updated:  5/22/2014
Bay State Clinical Trials, Inc.
mi
from
Watertown, MA
Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder
A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Solifenacin and Percutaneous Tibial Nerve Stimulation in Patients With Refractory Overactive Bladder
Status: Enrolling
Updated: 5/22/2014
Bay State Clinical Trials, Inc.
mi
from
Watertown, MA
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Visions Clinical Research
mi
from
Tuscon, AZ
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Visions Clinical Research
mi
from
Tuscon, AZ
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Peninsula Urology Center
mi
from
Atherton, CA
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Peninsula Urology Center
mi
from
Atherton, CA
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
San Bernadino Urological Association Medical Group
mi
from
San Bernadino, CA
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
San Bernadino Urological Association Medical Group
mi
from
San Bernadino, CA
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
9040 Friars Road
mi
from
San Diego, CA
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
9040 Friars Road
mi
from
San Diego, CA
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
South Florida Medical Research
mi
from
Aventura, FL
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
South Florida Medical Research
mi
from
Aventura, FL
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Visions Clinical Research
mi
from
Boynton Beach, FL
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Visions Clinical Research
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Florida Healthcare Research
mi
from
Ocala, FL
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Florida Healthcare Research
mi
from
Ocala, FL
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Southern Research Group, Centre Point Boulevard
mi
from
Tallahassee, FL
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Southern Research Group, Centre Point Boulevard
mi
from
Tallahassee, FL
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Atlanta Medical Research
mi
from
Alpharetta, GA
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Atlanta Medical Research
mi
from
Alpharetta, GA
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Urological Surgeons of IL
mi
from
Kankakee, IL
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Urological Surgeons of IL
mi
from
Kankakee, IL
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Regional Urology
mi
from
Shreveport, LA
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Regional Urology
mi
from
Shreveport, LA
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Accumed Research Associate
mi
from
Garden City, NY
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Accumed Research Associate
mi
from
Garden City, NY
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Hudson Valley Urology, PC
mi
from
Kingston, NY
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Hudson Valley Urology, PC
mi
from
Kingston, NY
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
New York Urological Associates, PC
mi
from
New York, NY
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
New York Urological Associates, PC
mi
from
New York, NY
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Hudson Valley Urology
mi
from
Poughkeepsie, NY
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Hudson Valley Urology
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Unifour Medical Research
mi
from
Hickory, NC
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Unifour Medical Research
mi
from
Hickory, NC
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
University of Pittsburg, Dept Urology
mi
from
Pittsburg, PA
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
University of Pittsburg, Dept Urology
mi
from
Pittsburg, PA
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
Volunteer Research Group
mi
from
Knoxville, TN
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
Volunteer Research Group
mi
from
Knoxville, TN
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
5920 Saratoga Boulevard
mi
from
Corpus Christi, TX
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
5920 Saratoga Boulevard
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
National Clinical Research, Inc.
mi
from
Richmond, VA
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
National Clinical Research, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated:  12/5/2014
801 W. 5th Avenue
mi
from
Spokane, WA
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Status: Enrolling
Updated: 12/5/2014
801 W. 5th Avenue
mi
from
Spokane, WA
Click here to add this to my saved trials